Introduction Breast cancer remains a significant scientific, clinical and societal challenge.
This gap analysis has reviewed and critically assessed enduring issues and new challenges …

It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against
tumours not located in bone. Mice transgenic for the activated ErbB‐2 oncogene were treated …

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells
in the bone marrow and the development of osteolytic bone disease. The present study …

Bone metastasis is a major cause of morbidity in persons with cancer. Complications
include pain, impaired mobility, pathological fracture, spinal cord compression, cranial nerve …

Tumour cells communicate with the cells of their microenvironment via a series of molecular
and cellular interactions to aid their progression to a malignant state and ultimately their …

Skeletal metastases are frequent complications of many cancers, causing bone complications
(fractures, bone pain, disability) that negatively affect the patient’s quality of life. Here, we …

Factors that aid survival of prostate cancer cells in the presence of the variouscategories of
cytotoxic cytokines present in tumors in vivo are largely unknown. Osteoprotegerin (OPG) is a …

Background The potent antiresorptive drug zoledronic acid (Zol) enhances the antitumor
effects of chemotherapy agents in vitro. We investigated the effects of clinically achievable …

Research using animal model systems has been instrumental in delivering improved
therapies for breast cancer, as well as in generating new insights into the mechanisms that …

Background We have recently identified interleukin 1B (IL-1B) as a potential biomarker for
predicting breast cancer patients at increased risk for developing bone metastasis. In mouse …